BIIB019 (Daclizumab High Yield Process) + Interferon beta-1a Placebo + Interferon beta-1a + Daclizumab High Yield Process Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsing-Remitting Multiple Sclerosis
Conditions
Relapsing-Remitting Multiple Sclerosis
Trial Timeline
May 1, 2010 → Jul 1, 2014
NCT ID
NCT01064401About BIIB019 (Daclizumab High Yield Process) + Interferon beta-1a Placebo + Interferon beta-1a + Daclizumab High Yield Process Placebo
BIIB019 (Daclizumab High Yield Process) + Interferon beta-1a Placebo + Interferon beta-1a + Daclizumab High Yield Process Placebo is a phase 3 stage product being developed by AbbVie for Relapsing-Remitting Multiple Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01064401. Target conditions include Relapsing-Remitting Multiple Sclerosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01064401 | Phase 3 | Completed |
Competing Products
20 competing products in Relapsing-Remitting Multiple Sclerosis